InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Kathiresan Sekar, Chief Executive Officer. Officer active across 1 company, notably Verve Therapeutics, Inc.. In total, 16 filings have been logged. Breakdown: 2 buys · 0 sell. Total volume traded: €80k. Activity tracked since 21 June 2021. The latest transaction was disclosed on 4 December 2024 (Don). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations16 total
33,000 sharesCommon StockSEC:0000950170-25-050563:0
30,000 shares0Common StockSEC:0000950170-24-133290:0
30,000 shares@ US$2.8710.1% of flowCommon StockSEC:0000950170-24-080012:0
50,000 shares@ US$1.398.9% of flowCommon StockSEC:0001209191-22-052799:0
50,000 shares@ US$1.398.5% of flowCommon StockSEC:0001209191-22-045447:0
50,000 shares@ US$1.398.6% of flowCommon StockSEC:0001209191-22-042871:0
160,000 shares0Common StockSEC:0001209191-22-042265:0
69,674 shares@ US$2.8735.5% of flowCommon StockSEC:0000899243-22-011767:0
1,870 shares@ US$1.390.3% of flowCommon StockSEC:0000899243-22-001203
1,870 shares@ US$1.390.5% of flowCommon StockSEC:0000899243-22-001203:0
42,000 shares@ US$1.396.5% of flowCommon StockSEC:0000899243-21-050032
42,000 shares@ US$1.3910.1% of flowCommon StockSEC:0000899243-21-050032:0
57,000 shares@ US$1.398.8% of flowCommon StockSEC:0000899243-21-049812
57,000 shares@ US$1.3913.8% of flowCommon StockSEC:0000899243-21-049812:0
2,500 shares@ US$19.005.0% of flowCommon StockSEC:0000899243-21-025070
Ideal exit: 18 Mar 2022 (T+270)
2,500 shares@ US$19.007.8% of flowCommon StockSEC:0000899243-21-025070:0
Ideal exit: 18 Mar 2022 (T+270)
16 of 16 declarations
About Kathiresan Sekar
Sekar Kathiresan is the Chief Executive Officer of Verve Therapeutics, Inc. In this role, he is responsible for the strategic and operational direction of the company. His expertise in biotechnology and ability to lead teams enable him to drive innovation and growth. He plays a key role in business development and stakeholder engagement.
